RXRX - Tilray resumed with an outperform rating Elanco and Shockwave upgraded and more in today's analyst action

Tilray resumed with an outperform ratingFollowing the closing its acquisition with Aphria earlier this month, Cowen has resumed coverage of Tilray (TLRY) with an outperform rating and $20 price target.That implies upside of ~43% from the stock's most recent close.Analyst Vivien Azer writes that Tilray is now the market share leader in Canada with "best-in-class profitability."She says the company has about a 19% share of the adult cannabis market, ~420 bps above its closest competitor.Also, the two companies compliment each other allowing for exposure into different cannabis forms, such as edibles and vaping, as well as into more provinces.Increase in pet visits and spending boosts ElancoElanco Animal Health (ELAN) is benefitting from an increase in the number of pets, along with more vet visits and increasing spend per visit, prompting Barclays to upgrade the stock to equal weight from underweight.Analyst Balaji Prasad is also raising his price target to $29

For further details see:

Tilray resumed with an outperform rating, Elanco and Shockwave upgraded, and more in today's analyst action